Two weeks of treatment with deprenyl (selegiline) does not prolong l‐dopa effect in parkinsonian patients
- 1 September 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 38 (9) , 1387
- https://doi.org/10.1212/wnl.38.9.1387
Abstract
We investigated the influence of 2 weeks of treatment with deprenyl on the acute effect of a single dose of 200 mg of l-dopa in a double-blind cross-over placebo-controlled trial in 16 parkinsonian patients with wearing-off phenomena. Deprenyl induced no significant benefit in the duration or the maximal improvement of l-dopa's effect. Moreover, deprenyl treatment did not improve the patient's motor status.This publication has 9 references indexed in Scilit:
- The effect of L-Deprenyl on on-off phenomena in Parkinson's diseaseActa Neurologica Scandinavica, 2009
- Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease A double-blind crossover trial.Acta Neurologica Scandinavica, 1987
- N‐propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenylBritish Journal of Pharmacology, 1987
- Mapping Human Brain Monoamine Oxidase A and B with11C-Labeled Suicide Inactivators and PETScience, 1987
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- Metabolism of (‐) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefitNeurology, 1982
- Deprenyl in Parkinson diseaseNeurology, 1981
- Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.Journal of Neurology, Neurosurgery & Psychiatry, 1980
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977